Qiagen said Friday after the close of the market that it has acquired an exclusive worldwide license from Johns Hopkins University for detection of the AR-V7 biomarker in all sample and cell types using nucleic acid tests such as PCR or next-generation sequencing.
As a result, Qiagen will commercialize its research-use-only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant 7 from liquid biopsies to investigate resistance to potential drugs for advanced prostate cancer.